SCHEMBL26305201

SCHEMBL26305201

CCCCCCCC/C=C\CCCCCCCCOCC(OCCCCCCCC/C=C\CCCCCCCC)C(O)CCCCCCCCCCCC

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 3/20 0.49
LPAR3 Q9UBY5 3/20 0.49
ALDH1A1 P00352 1/20 0.47
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
USP2 O75604 1/20 0.45
SPHK1 Q9NYA1 1/20 0.44
HTT P42858 1/20 0.44
P2RY10 O00398 1/20 0.44
LPAR2 Q9HBW0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10010141 0.96 ALDH1A1 (0.54) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL10010145 0.96 ALDH1A1 (0.54) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL8636549 0.91 USP2 (0.53) LPAR1LPAR3USP2SPHK1HTT
SCHEMBL7714993 0.88 LPAR1 (0.51) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL26305198 0.85 LPAR1 (0.46) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL19019736 0.84 ALDH1A1 (0.56) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL29168461 0.83 LPAR1 (0.49) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL29144463 0.83 LPAR1 (0.49) LPAR1LPAR3ALDH1A1CNR1CNR2
SCHEMBL669995 0.82 CYP2D6 (0.50) LPAR1LPAR3USP2SPHK1HTT
SCHEMBL29277273 0.82 LPAR1 (0.48) LPAR1LPAR3ALDH1A1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295097-A1 LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 US disclosed
US-20230295097-A1 LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 US disclosed
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 US disclosed
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 US disclosed
CN-116194084-A Cleavable lipid compounds, compositions containing the same and uses thereof 赛诺菲巴斯德有限公司 2023-05-30 CN disclosed
EP-4182296-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF Sanofi Pasteur (FR) 2023-05-24 EP disclosed
EP-4182302-A1 LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF Sanofi Pasteur (FR) 2023-05-24 EP disclosed
CN-116134020-A Lipid compounds comprising at least one terminal group of formula-NH-CX-A or-NH-CX-NH-A, compositions containing them and uses thereof 赛诺菲巴斯德有限公司 2023-05-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF MTTP, CETP, LNPEP LPAR1 64/4885LPAR3 103/4885ALDH1A1 2000/4885
US-20230295097-A1 LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF PRDX5, ANXA5, PRDX1 LPAR1 168/4885LPAR3 378/4885ALDH1A1 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.